Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae Treated with Ceftazidime-Avibactam: A Retrospective Study
Lingchun Zhang,Yani Ma,Chenglong Zhao,Shujuan Zhao,Lulu Zhao,Yuxin Yang,Yuhan Wang,Haiyang Meng,Jun Sun
DOI: https://doi.org/10.2147/idr.s445243
2024-01-26
Infection and Drug Resistance
Abstract:Lingchun Zhang, 1, &ast Yani Ma, 2, &ast Chenglong Zhao, 1 Shujuan Zhao, 1 Lulu Zhao, 3 Yuxin Yang, 4 Yuhan Wang, 5 Haiyang Meng, 6 Jun Sun 1 1 Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, People's Republic of China; 2 Department of Pharmacy, the First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China; 3 Department of Pharmacy, Gongyi People's Hospital, Zhengzhou, People's Republic of China; 4 Department of Pharmacy, Anyang Ophthalmic Hospital, Anyang, People's Republic of China; 5 Department of Pharmacy, Henan Integrative Medicine Hospital, Zhengzhou, People's Republic of China; 6 Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Sun, Department of Pharmacy, Henan Provincial People's Hospital, No. 7 Weiwu Road, Zhengzhou, People's Republic of China, Tel +86 13683827203, Email Purpose: Carbapenem-Resistant Klebsiella pneumoniae (CRKP) is a significant public health threat, because it is associated with substantial morbidity and mortality. However, the risk factors associated with treatment failure of ceftazidime-avibactam (CAZ-AVI) and the need for CAZ-AVI-based combination remain unclear. Methods: We conducted a retrospective study of critically ill patients (age: > 18 years) diagnosed with CRKP infections and treated with CAZ-AVI for at least 24 h between June 2020 and December 2022 at Henan Provincial People's Hospital. Results: This study included a total of 103 patients who received CAZ-AVI. Of these, 91 (88.3%) patients received the standard dosage of 2.5 g every q8h, while only 20 (19.4%) received monotherapy. The Kaplan–Meier curves showed that the all-cause 30-day mortality was significantly higher among patients who experienced septic shock than those who did not. There was no significant difference in mortality between monotherapy and combination therapy. Dose reduction of CAZ-AVI was associated with a significantly increased mortality rate. Independent risk factors for the 30-day mortality included higher APACHE II score (HR: 1.084, 95% CI: 1.024– 1.147, p = 0.005) and lower lymphocyte count (HR: 0.247, 95% CI: 0.093– 0.655, p = 0.005). Conversely, a combination therapy regimen containing carbapenems was associated with lower mortality (HR: 0.273, 95% CI: 0.086– 0.869, p = 0.028). Conclusion: Our study suggests that CAZ-AVI provides clinical benefits in terms of survival and clinical response in critically ill patients with CRKP infection. A higher APACHE II score and lower lymphocyte count were associated with 30-day mortality, while the combination therapy regimen containing carbapenems was the only protective factor. CAZ-AVI dose reduction was associated with an increased mortality rate. Futher large-scale studies are needed to validate these findings. Keywords: carbapenem-resistant Klebsiella pneumoniae , ceftazidime-avibactam, retrospective study, combination therapy Carbapenem-resistant Enterobacteriaceae (CRE), particularly Carbapenem-Resistant Klebsiella pneumoniae (CRKP), pose a significant public health threat because of their contribution to substantial morbidity and mortality. 1,2 Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) showed a progressive increase in the proportion of CRKP isolates from clinical specimens, increasing from 2.2% in 2009 to 19.4% in 2012. 3 Similarly, in China, CRKP has emerged as a major concern, with K. pneumoniae resistance to imipenem swiftly escalating from 15.6% in 2015 to 29% in 2023, according to information from the China Antimicrobial Surveillance Network (CHINET, www.chinets.com ). However, treating CRKP infections in developing countries presents significant challenges owing to limited access to new therapeutic agents. Ceftazidime-avibactam (CAZ-AVI), a novel β-lactam/β-lactamase inhibitor combination, was approved for use in China in September 2019. 4 Avibactam is a non-β-lactam, β-lactamase inhibitor, which exhibits activity against Ambler class A (eg, extended-spectrum-β-lactamases [ESBLs], K. pneumoniae carbapenemases [KPCs]) and class C (AmpC) and some class D(OXA) enzymes. 5,6 In China, CAZ-AVI has been approved for the treatment of complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), and other infections caused by multidrug-resista -Abstract Truncated-
pharmacology & pharmacy,infectious diseases